Hindustan Bio Sciences Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Hindustan Bio Sciences Ltd is ₹ 9.06 as of 30 Apr 15:30 . The P/E Ratio of Hindustan Bio Sciences Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Hindustan Bio Sciences Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Hindustan Bio Sciences Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Hindustan Bio Sciences Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Hindustan Bio Sciences Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Hindustan Bio Sciences Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Ltd (Formerly known Hindustan Softel Ltd) was incorporated as Public Limited Company on December 16, 1991.
The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified operations in pharmaceutical and biotechnology sectors.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates. Previously, it was engaged in cement manufacturing and due to sluggish in the industry the company diversified its business into Bio Technology & Pharmaceuticals activities and the name of the Company was changed from Garuda Cements to Hindustan Bio-Sciences Ltd. In 2001, it diversified into software field and subsequently changed its name to Hindustan Softel Limited which presently got changed into Hindustan Bio Sciences Ltd.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Hindustan Bio Sciences Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Hindustan Bio Sciences Ltd or Sanofi India Ltd?

Market cap of Hindustan Bio Sciences Ltd is 9 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Hindustan Bio Sciences Ltd and Sanofi India Ltd?

The stock performance of Hindustan Bio Sciences Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Hindustan Bio Sciences Ltd and Sanofi India Ltd?

As of May 3, 2026, the Hindustan Bio Sciences Ltd stock price is INR ₹9.06. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Hindustan Bio Sciences Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Hindustan Bio Sciences Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.